For research use only. Not for therapeutic Use.
Dextrothyroxine (trade name Choloxin) saw research as an cholesterol-lowering drug but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles. (Source: https://en.wikipedia.org/wiki/Dextrothyroxine).
| Catalog Number | R046180 |
| CAS Number | 51-49-0 |
| Synonyms | O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine; 3,3’,5,5’-Tetraiodo-D-thyronine; Dextrothyroxine; |
| Molecular Formula | C15H11I4NO4 |
| Purity | ≥95% |
| Target | Endogenous Metabolite |
| Storage | -20°C |
| IUPAC Name | (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid |
| InChI | InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1 |
| InChIKey | XUIIKFGFIJCVMT-GFCCVEGCSA-N |
| SMILES | C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N |
| Reference | </br>1:9 years follow-up of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of D-thyroxine and triiodothyroacetic acid (TRIAC). Guran T, Turan S, Bircan R, Bereket A.J Pediatr Endocrinol Metab. 2009 Oct;22(10):971-8. PMID: 20020587 </br>2:Simultaneous determination of l-thyroxine (l-T(4)), d-thyroxine (d-T(4)), and l-triiodothyronine (l-T(3)) using a sensors/sequential injection analysis system. Stefan RI, van Staden JF, Aboul-Enein HY.Talanta. 2004 Sep 8;64(1):151-5. doi: 10.1016/j.talanta.2004.01.024. PMID: 18969581 </br>3:Widespread expression of the mRNA encoding a novel vitamin D/thyroxine dual binding protein in the turtle Trachemys scripta. Whitworth DJ, Hunt L, Licht P.Gen Comp Endocrinol. 2000 May;118(2):354-8. PMID: 10890574 </br>4:D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, Nauck M, März W, Wieland H, Bommer J.J Am Soc Nephrol. 1998 Jan;9(1):90-6. PMID: 9440092 Free Article</br>5:Large somatostatin-insensitive thyrotrophin-secreting pituitary tumour responsive to D-thyroxine and dopamine agonists. Karlsson FA, Burman P, Kämpe O, Westlin JE, Wide L.Acta Endocrinol (Copenh). 1993 Oct;129(4):291-5. PMID: 7901958 </br>6:Purified D-thyroxine in athyreotic patients. Hamon P, Dingeon B, Jiang NS, Orgiazzi J.Lancet. 1993 Jun 5;341(8858):1477. No abstract available. PMID: 8099168 </br>7:Effect of L-thyroxine (LT4) and D-thyroxine (DT4) on cardiac function and high-energy phosphate metabolism: a 31P NMR study. Sandhu GS, Steele R, Gonnella NC.Magn Reson Med. 1991 Mar;18(1):237-43. PMID: 2062236 </br>8:Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D thyroxine: a study in three patients. Dorey F, Strauch G, Gayno JP.Clin Endocrinol (Oxf). 1990 Feb;32(2):221-8. PMID: 2189602 </br>9:Hyperthyroidism due to selective pituitary resistance to thyroid hormones in a 15-month-old boy: efficacy of D-thyroxine therapy. Hamon P, Bovier-Lapierre M, Robert M, Peynaud D, Pugeat M, Orgiazzi J.J Clin Endocrinol Metab. 1988 Nov;67(5):1089-93. PMID: 3182960 </br>10:Treatment with D-thyroxine of patients with glycogen storage diseases type VI and VIa. Cabalska B, Zbieg-Sendecka E, Kobryń A, Pronicka E, Pieniazek D.Mater Med Pol. 1987 Oct-Dec;19(4):290-3. No abstract available. PMID: 3483883 |
